Vaccination, seizures and 'vaccine damage'

Current Opinion in Neurology

Volumn 20, Issue 2, 2007, Pages 181-187

  Brown, Natasha J ^a,b,c   Berkovic, Samuel F ^a   Scheffer, Ingrid E ^a,b,d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c BARWON HEALTH   (Australia)

^d AUSTIN HEALTH   (Australia)

Author keywords

Autism; Encephalopathy; Seizure; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; MEASLES MUMPS RUBELLA VACCINE; PERTUSSIS VACCINE; SODIUM CHANNEL;

AUTISM; BRAIN DAMAGE; BRAIN DISEASE; CONVULSION; DRUG SAFETY; ENCEPHALITIS; FEBRILE CONVULSION; FEVER; GENE MUTATION; HUMAN; IMMUNIZATION; INFANTILE SPASM; OUTCOME ASSESSMENT; REVIEW; REYE SYNDROME; RISK ASSESSMENT; SEIZURE; VACCINATION;

EID: 33947169151     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3280555160     Document Type: Review

References (74)

1. Asaria P, MacMahon E. Measles in the United Kingdom: can we eradicate it by 2010? BMJ 2006; 333:890-895.
2. CDC. Recommended Childhood and Adolescent Immunization Schedule: United States. MMWR 2006; 54:Q1-Q4.
3. Torvaldsen SH, Hull BP, McIntyre PB. Using the Australian Childhood Immunisation Register to track the transition from whole-cell to acellular pertussis vaccines. Communicable Disease Intelligence 2002; 26:581-583.
4. Avdicova M, Prikazsky V, Hudeckova H, et al. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr 2002; 161:581-587.
5. Braun MM, Mootrey GT, Salive ME, et al. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics 2000; 106:E51.
6. Rosenthal S, Chen R, Hadler S. The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment. Arch Pediatr Adolesc Med 1996; 150:457-460.
7. Kuno-Sakai H, Kimura M. Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization. Pediatr Int 2004; 46:650-655.
8. Ball R, Halsey N, Braun MM, et al. Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the vaccine: Adverse Event Reporting System. J Clin Epidemiol 2002; 55:819-824.
9. Kohl KS, Marcy SM, Blum M, et al. Fever after immunization: current concepts and improved future scientific understanding. Clin Infect Dis 2004; 39:389-394.
10. Pollock TM, Miller E, Mortimer JY, Smith G. Symptoms after primary immunisation with DTP and with DT vaccine. Lancet 1984; 2:146-149.
11. Blumberg DA, Lewis K, Mink CM, et al. Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying. Pediatrics 1993; 91:1158-1165.
12. Cody CL, Baraff LJ, Cherry JD, et al. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981; 68:650-660.
13. Walker AM, Jick H, Perera DR, et al. Neurologic events following diphtheria-tetanus-pertussis immunization. Pediatrics 1988; 81:345-349.
14. Griffin MR, Ray WA, Mortimer EA, et al. Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine. JAMA 1990; 263:1641-1645.
15. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995; 345:567-569.
16. Barlow WE, Davis RL, Glasser JW, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001; 345:656-661.
17. Griffin MR, Ray WA, Mortimer EA, et al. Risk of seizures after measles-mumps-rubella immunization. Pediatrics 1991; 88:881-885.
18. Vestergaard M, Hviid A, Madsen KM, et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA 2004; 292:351-357.
19. Olin P, Rasmussen F, Gustafsson L, et al. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 1997; 350:1569-1577.
20. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996; 334:341-348.
21. Jackson LA, Carste BA, Malais D, Froeschle J. Retrospective population-based assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids. Pediatr Inf Dis J 2002; 21:781-786.
22. Kitchin N, Southern J, Morris R, et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine 2006; 24:3964-3970.
23. CDC. Surveillance Summaries. MMWR 2003; 52:SS-1.
24. Le Saux N, Barrowman NJ, Moore DL, et al. Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics 2003; 112:e348-e353.
25. Annegers JF, Hauser WA, Shirts SB, Kurland LT. Factors prognostic of unprovoked seizures after febrile convulsions. N Engl J Med 1987; 316:493-498.
26. Baraff LJ, Shields WD, Beckwith L, et al. Infants and children with convulsions and hypotonic-hyporesponsive episodes following diphtheria-tetanus-pertussis immunization: follow-up evaluation. Pediatrics 1988; 81:789-794.
27. NH&MRC. The Australian Immunisation Handbook. Canberra: Commonwealth of Australia; 2003.
28. CDC. MMWR Recommendations and Reports 2006; 55:1-48.
29. Bonhoeffer J, Gold MS, Heijbel H, et al. Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 2004; 22:563-568.
30. Lawrence GL, Boyd I, McIntyre PB, Issacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2004. Communicable Disease Intelligence 2005; 29:248-262.
31. Goodwin H, Nash M, Gold M, et al. Vaccination of children following a previous hypotonic-hyporesponsive episode. J Paediatr Child Health 1999; 35:549-552.
32. Madsen T. Vaccination against whooping cough. JAMA 1933; 101:187-188.
33. Kulenkampff M, Schwartzman JS, Wilson J. Neurological complications of pertussis inoculation. Arch Dis Child 1974; 49:46-49.
34. Miller DL, Ross EM, Alderslade R, et al. Pertussis immunisation and serious acute neurological illness in children. BMJ 1981; 282:1595-1599.
35. Marcuse EK, Wentz KR. The NCES reconsidered: Summary of a 1989 workshop. Vaccine 1990; 8:531-535.
36. Griffith AH. Permanent brain damage and pertussis vaccination: is the end of the saga in sight? Vaccine 1989; 7:199-210.
37. Pollock TM, Morris J. A 7-year survey of disorders attributed to vaccination in North West Thames region. Lancet 1983; 1:753-757.
38. Moore DL, Le Saux N, Scheifele D, et al. Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993-2002. Pediatr Inf Dis J 2004; 23:568-571.
39. Gale JL, Thapa PB, Wassilak SG, et al. Risk of serious acute neurological illness after immunization with diphtheria-tetanus-pertussis vaccine. A population-based case-control study. JAMA 1994; 271:37-41.
40. Ray P, Hayward J, Michelson D, et al. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study. Pediatr Inf Dis J 2006; 25:768-773. •• This retrospective case-control study examined 452 cases of encephalopathy and determined the risk of recent vaccination with MMR or DTwP. Neither vaccine was administered more commonly to cases than controls. This provides further evidence against the NCES conclusions.
41. Golden GS. Pertussis vaccine and injury to the brain. J Pediatr 1990; 116:854-861.
42. Bellman MH, Ross EM, Miller DL. Infantile spasms and pertussis immunisation. Lancet 1983; 1:1031-1034.
43. Shields WD, Nielsen C, Buch D, et al. Relationship of pertussis immunization to the onset of neurologic disorders: a retrospective epidemiologic study. J Pediatr 1988; 113:801-805.
44. American Academy of Pediatrics Committee on Infectious Diseases. The relationship between pertussis vaccine and central nervous system sequelae: continuing assessment. Pediatrics 1996; 97:279-281.
45. World Health Organization. Pertussis Vaccines: WHO Position Paper. Weekly Epidemiological Record 2005; 80:31-39. • This document summarizes the current WHO stance on pertussis, examines extent of the pertussis problem worldwide and the impact, efficacy and toxicity of both acellular and whole cell pertussis vaccines.
46. Dravet C, Bureau M, Oguni H, et al. Severe myoclonic epilepsy in infancy (Dravet syndrome). In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, editors. Epileptic syndromes in infancy, childhood and adolescence, 4th ed. Montrouge: John Libbey Eurotext Ltd; 2005. pp. 89-113.
47. Doose H, Lunau H, Castiglione E, Waltz S. Severe idiopathic generalized epilepsy of infancy with generalized tonic-clonic seizures. Neuropediatrics 1998; 29:229-238.
48. Mulley JC, Scheffer IE, Petrou S, et al. SCN1A mutations and epilepsy. Hum Mutat 2005; 25:535-542.
49. Claes L, Del-Favero J, Ceulemans B, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001; 68:1327-1332.
50. Nieto-Barrera M, Lillo MM, Rodriguez-Collado C, et al. Severe myoclonic epilepsy in childhood. Rev Neurol 2000; 30:620-624.
51. Berkovic SF, Harkin L, McMahon JM, et al. De-novo mutations of the sodium channel gene SCN1A in alleged vaccine encephalopathy: a retrospective study. Lancet Neurol 2006; 5:488-492. •• This paper describes 14 cases of alleged vaccine encephalopathy showing that 11 had mutations of the SCN1A gene and the phenotype of Dravet syndrome.
52. Danielsson S, Gillberg IC, Billstedt E, et al. Epilepsy in young adults with autism: a prospective population-based follow-up study of 120 individuals diagnosed in childhood. Epilepsia 2005; 46:918-923. • This was a large prospective study of subjects with ASD examining cumulative incidence of epilepsy, most commonly associated intellectual disability.
53. Williams JG, Higgins JPT, Brayne CEG. Systematic review of prevalence studies of autism spectrum disorders. Arch Dis Child 2006; 91:8-15.
54. Croen LA, Grether JK, Hoogstrate J, Selvin S. The changing prevalence of autism in California. J Autism Dev Disord 2002; 32:207-215.
55. Werner E, Dawson G, Osterling J, Dinno N. Brief report: Recognition of autism spectrum disorder before one year of age: a retrospective study based on home videotapes. J Autism Dev Disord 2000; 30:157-162.
56. Osterling J, Dawson G. Early recognition of children with autism: a study of first birthday home videotapes. J Autism Dev Disord 1994; 24:247-257.
57. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, nonspecific colitis, and pervasive developmental disorder in children. Lancet 1998; 351:637-641.
58. Uhlmann V, Martin CM, Sheils O, et al. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. Mol Pathol 2002; 55:84-90.
59. Murch SH, Anthony A, Casson DH, et al. Retraction of an interpretation. Lancet 2004; 363:750.
60. Geier DA, Geier MR. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. Pediatr Rehabil 2003; 6:97-102.
61. Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002; 347:1477-1482.
62. Taylor B, Miller E, Lingam R, et al. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 2002; 324:393-396.
63. Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999; 353:2026-2029.
64. Kaye JA, del Mar Melero-Montes M, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 2001; 322:460-463.
65. Madsen KM, Lauritsen MB, Pedersen CB, et al. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics 2003; 112 (3 Pt 1):604-606.
66. Global Advisory Committee on Vaccine Safety. Statement on thiomersal, July 2006. Geneva: World Health Organization; 2006.
67. Bailey A, Le Couteur A, Gottesman I, et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 1995; 25:63-77.
68. Bolton P, Macdonald H, Pickles A, et al. A case-control family history study of autism. J Child Psychol Psychiatry 1994; 35:877-900.
69. Persico AM, Bourgeron T. Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. Trends Neurosci 2006; 29:349-358.
70. Skaar DA, Shao Y, Haines JL, et al. Analysis of the RELN gene as a genetic risk factor for autism. Mol Psychiatry 2005; 10:563-571.
71. Chih B, Afridi SK, Clark L, Scheiffele P. Disorder-associated mutations lead to functional inactivation of neuroligins. Hum Mol Genet 2004; 13:1471-1477.
72. Jamain S, Quach H, Betancur C, et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet 2003; 34:27-29.
73. Friederichs V, Cameron JC, Robertson C. Impact of adverse publicity on MMR vaccine uptake: a population based analysis of vaccine uptake records for one million children, born 1987-2004. Arch Dis Child 2006; 91:465-468. • This population-based study examined MMR vaccine coverage in Scotland. Findings are of increased susceptibility amongst preschool children and total coverage below that required for herd immunity.
74. Eldred BE, Dean AJ, McGuire TM, Nash AL. Vaccine components and constituents: responding to consumer concerns. Med J Aust 2006; 184:170-175.